Sertindole is an atypical antipsychotic with a very low incidence of movement disorder side effects, anticholinergic effects and sedation, despite this it is associated with a higher rate of discontinuation, weight gain (same sort of neighbourhood as quetiapine), prolactin elevation (comparable to lurasidone, making it above average in its propensity for causing this side effect) and a very high rate of QT interval prolongation. For the last reason it was initially discontinued from the European market in 1998, two years after its introduction to this market. It was later re-introduced >2005, although it has been re-discontinued in the U.K., Australia and the New Zealand since then.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- TGA-eBS; Serdolect (CMI, PI).
- ↑ "Sertindole". Australian Prescriber 34 (3): 89–91. June 2011.
- ↑ Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.". Lancet 382 (9896): 951–62. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3.